INTRODUCTION
Assisted ventilation of immature lungs creates a dilemma of steering between underventilation and consequent alveolar hypoventilation or overventilation and lung injury. 1 -4 Two concepts in immature lung ventilation are pressure-limited and volume-controlled ventilation.
In pressure-limited ventilation, the clinician determines the pressure with which the infant is ventilated. This allows for a more stable peak inspiratory pressure (PIP) to avoid overdistension and its potential for lung injury. In volume-controlled ventilation, the clinician sets a tidal volume (V T ), which the ventilator then delivers, using whatever pressure is necessary. This would result in a more consistent V T delivered to the patient as the lung compliance changes and would theoretically avoid lung overinflation.
Pressure support ventilation with volume guarantee (PSV+VG) has recently become an available option for neonatal ventilation. It provides a possible means to decrease the ventilatory pressure needed to achieve a given V T . PSV gives the patient the ability to set his or her own inspiratory time, respiratory rate, and minute ventilation (V E ). By adding VG to this mode, a target V T is set by the physician. The pressure needed to achieve this volume is automatically adjusted with each breath to maintain the target V T while using the least amount of positive pressure. It is possible that, by having a more consistent V T , less positive pressure will be needed to ventilate an infant. It is unknown if this reduction in cycling pressure would result in less lung distension and injury.
Recently, several clinical trials have been published, which have compared a volume ventilatory mode with conventional mechanical ventilation strategies. 5 -8 In general, they have shown that a more consistent V T can be achieved using a volume strategy. Other results have included a lower mean airway pressure (MAP), without any compromise in oxygenation.
One limitation with previous studies comparing different modes of assisted ventilation has been not knowing the end expiratory volume (EEV). EEV is decreased with respiratory distress syndrome (RDS), and surfactant therapy has been shown not only to improve oxygenation but also to increase EEV. 9 -13 Knowledge of EEV, coupled with traditional airway pressure measurements, allows for adjustments to the ventilator to increase the EEV, e.g., when surfactant therapy is associated with less than expected improvement.
Based upon the rationale that PSV+VG would limit the PIP, but would provide equivalent pulmonary gas exchange compared to synchronized intermittent mandatory ventilation (SIMV), we conducted a randomized crossover study to test the hypothesis that PSV+VG would be associated with improvement in oxygen and carbon dioxide exchange, and with improvement in specific dynamic
OBJECTIVE:
To compare pressure support ventilation ( PSV ) with volume guarantee ( VG ) to synchronized intermittent mandatory ventilation ( SIMV ) in infants with respiratory distress syndrome ( RDS ).
STUDY DESIGN:
A randomized, crossover study design was used. We enrolled 14 infants [ BW ( mean ± SD ) 2.5 ± 0.7 kg, GA 34 ± 2 weeks, age 49 ± 26 hours ]. Subjects received 4 hours of each mode of ventilation, with the first mode selected randomly. End expiratory volume ( EEV ) was measured during both ventilatory modes. 
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Patient Exclusion Criteria
Infants were excluded if they had historical or radiographic evidence of meconium aspiration or pneumothorax. They were also excluded if they needed intermittent or continuous sedation, as the ventilator mode in study is patient-triggered.
Study Approval
The study was approved by the CMH-UMKC Institutional Review Board. Informed consent was obtained from parents before enrollment.
Study Design
A randomized, crossover study design was used to compare the ventilatory modes. Randomization was performed using a random number table with results placed in sealed opaque envelopes to indicate the order of either PSV+VG or SIMV. The study began at least 6 hours after the last dose of surfactant had been given. Subjects were treated for 4 hours with the first mode of ventilation. Arterial blood gas (ABG) tensions and pH were sampled at least every 2 hours, with the rate of assisted ventilation adjusted to attempt to maintain the p a CO 2 within 5 mm Hg of the value at enrollment. During the PSV+VG interval, all infants received a preset V T of 5 ml/kg. Frequent (every 15 minutes) measurements of the PIP, PEEP, V E , and V T were recorded. The SpO 2 and the directly measured arterial blood pressure were monitored continuously. During PSV+VG, the PIP and T I can vary with each breath.
During the SIMV mode, T I was set at 0.35 seconds. The goal for the V T with synchronized breaths was 4.0 to 5.0 ml/kg; the PIP was set to achieve this V T -typically 18 to 19 cm H 2 O.
At the end of the initial 4 hours, the EEV was measured using a real time computerized helium dilution method. Subjects were then crossed over to the other mode of ventilation for 4 hours, with the same variables being measured. There was no ''washout'' period between the changes in the ventilatory modes.
The assisted ventilation device (Babylog 8000 Plus ventilator; Drager, Telford, PA), which was used in this study, is equipped with software that calculates and continuously displays the V T , MAP, V E , and dynamic compliance. These measurements were recorded at the time of each ABG measurement after averaging the values for the previous 5 minutes recorded each minute. sCdyn was calculated as: V T /PIPÀPEEP. This value was normalized by EEV. The ventilator also measures the leak around the endotracheal tube and displays this value. Measured leak was zero, at and before the recorded measurements, as leak could affect the EEV measurement.
14 Measurement of EEV EEV was measured using a specifically designed infant breathing circuit (Equilibrated Bio Systems, Melville, NY). The device consists of a high-speed, low-dead-space helium analyzer, a remotely controlled four-way switching valve attached to a rebreathing reservoir in an airtight cylinder, and a PC-compatible computer program to time the test functions and calculate the EEV. The endotracheal tube of each infant, the ventilator, and the rebreathing bag are all connected through the four-way valve. After calibration of the system, the investigators filled the circuit with a mixture of 10% helium and 90% oxygen. The infant was then connected to the circuit and ventilated directly through the ventilatory breathing circuit or, following the position change of the valve, ventilated from the rebreathing bag. The rebreathing bag is inflated and deflated by the ventilator so the infant is supported by the ventilator at all times. The infant breathed from the bag for 30 to 40 seconds or until the final helium concentration reached equilibrium, which is observed as a plateau on the bedside video screen. The initial and final helium concentrations were used to calculate EEV. The results were corrected for dead space and then further corrected to body temperature at ambient pressure and saturated with water vapor. The EEV was measured in triplicate in each infant, with an interval of at least 10 minutes between measurements. These results were then averaged. There was <10% variance among the three values obtained at each measurement point.
Outcomes
The primary outcome variable was V E . Study design called for similar arterial pCO 2 from which the assumption was drawn that alveolar ventilation (VA) was equal. Secondary outcomes included arterial/ alveolar oxygen tension (a/A) ratio, end expiratory lung volume, and sCdyn (sCdyn=dynamic compliance/EEV).
Statistical Analysis
A modified power analysis was undertaken before initiation of the study. A 25% improvement in V E with no change in PIP was considered clinically relevant. By using historical controls from a chart review of preterm infants with RDS, we calculated that a sample size of 25 patients would lend a power of 80% to a study designed to detect a 25% improvement in V E , with VA constant, with PSV+VG. The study as designed was not blinded.
We performed an analysis after half the patients were enrolled and, based on these results, would either continue to the original goal of 25 patients or stop. A 14th patient was enrolled and data were obtained before the analysis took place. Thus, we included data for all 14. We stopped enrolling patients after that analysis showed very little likelihood of finding a significant improvement in V E with PSV+VG.
Statistical analysis was performed using SPSS for Windows, version 9.0 (SPSS, Chicago, IL). The outcome variables were measured both in PSV+VG and SIMV and directly compared using paired t tests. A p value <0.05 was considered significant.
RESULTS
During the study period, 38 infants were screened for eligibility based upon age and presence of RDS. Eighteen eligible infants were identified at a time that all study equipment and personnel were available. Informed consent was obtained for 14 infants. Reasons for exclusion from the study for the other four infants included refusal of parental consent (n=1) and air leak around the endotracheal tube (n=3). The infants screened and excluded were not different from the ones studied in any clinical parameter (data not shown).
The study population consisted of infants who were 34±2 (mean±SD) weeks' gestation (median, 34 weeks; range, 30-37 weeks) and 2.5±0.7 kg (median, 2.6 kg; range, 1.5-3.7 kg). None of the infants studied had received prenatal steroids. All had been treated with one or two doses of surfactant. The infants were enrolled at 46±26 hours of life (median, 41 hours; range, 13-120 hours) ( Table 1) In order to assess how each mode provided assisted ventilation, the V E was calculated by averaging values obtained every 15 minutes for the final hour before the ABG measurement at the end of each 4-hour epoch. The mean PIP, PEEP, T I , ventilator rate, and V T are shown at the end of each trial epoch ( Table 2 ). As each infant was neither sedated nor paralyzed, breaths were generated spontaneously in addition to ventilator-assisted breaths. Both contribute to V E and both were recorded. Mean V E was higher during PSV+VG than during SIMV (0.69±0.3 vs 0.59±0.2 l/min) ( p=0.012, 95% confidence interval À0.177 to À0.027) (Figure 1 ). The arterial pCO 2 was the same: SIMV, 40.4±5 vs PSV, 40.9±5 mm Hg (Figure 2) .
To compare the ability of each mode to support oxygenation, the a/A ratios of each ABG were analyzed. The mean a/A ratios during SIMV and PSV+VG were 0.40 and 0.37, respectively ( Figure 3 ). Paired t test comparison revealed p=0.171 (95% confidence interval À0.019 to 0.094).
The sCdyn was used as a measure of compliance during each mode of ventilation. The mean sCdyn in SIMV was 0.0210 ml/mm Hg per ml EEV and was 0.0193 ml/mm Hg per ml EEV in PSV+VG ( p=0.313, 95% confidence interval À0.002 to 0.005) (Figure 4 ). The EEV ( Figure 5 ) revealed a significant decrease during the PSV+VG mode ( p=0.011, 18±2 vs 16±2 ml/kg, 95% confidence interval 0.538 to 3.42). The MAP ( Figure 6 ) was significantly increased during the PSV+VG mode ( p=0.023, 95% confidence interval À1.45 to À0.129).
DISCUSSION
PSV and VG are two newer modes of assisted ventilation for neonates. PSV offers the patient the ability to set his own inspiratory time, respiratory rate, and V E . In VG, a target V T is set, and the pressure needed to deliver that volume is continually being adjusted. By combining these two modes, the lowest possible positive pressure is used to achieve a stable V T , while maintaining equivalent oxygenation and ventilation. However, no definitive prospective studies have compared PSV+VG to either SIMV or HFOV (or both) to demonstrate a clinically relevant outcome, e.g., reduced severity of chronic lung disease. Before such definitive studies can be undertaken, more data in preterm infants need to be evaluated to allow rational study designs. The present report is designed to add to the relevant literature.
In our randomized, crossover design, we used the patient as his or her own control and compared measurements of oxygenation, ventilation, and compliance during PSV+VG and during SIMV. We specifically chose a homogenous patient population with uncomplicated RDS in the improving stages of their disease process. They were larger premature infants who demonstrated respiratory failure and were treated with one or two doses of surfactant. They were also enrolled at a time significantly removed from surfactant therapy to minimize the likelihood of large intrastudy changes in their lung compliance.
We designed our study differently from previous trials 5,7 that compared SIMV and PSV+VG. Our crossover epochs were of a longer duration. Our study population consisted of larger premature infants, but closer to the time of birth. This enabled us to study uncomplicated RDS without bringing the very heterogenous aspects of early chronic lung disease into the study population. Lastly, and uniquely, we measured the EEV with each mode of ventilation and were able to compare lung volumes in the two modes.
We found no advantage in pulmonary oxygen exchange with PSV+VG as measured by the a/A ratio. The a/A ratio has the advantage of being easily calculated, but is physiologically imprecise. A depressed ratio, as occurs in RDS, can result from a variable combination of shunt and low ventilation/perfusion areas in the lung. The similarity in the a/A ratio occurred in association with significantly higher MAP during PSV+VG. In previous trials comparing VG alone to SIMV, 5,7 a significant decrease was seen in the MAP while using VG. We did not find any improvement in PIP or MAP when using the combination of PSV+VG.
VA, as assessed by the p a CO 2 , did not differ between the modes by design. However, in order to achieve the similar p a CO 2 , V E was significantly increased in PSV+VG (Figure 1 ). This was mainly a reflection of the increased respiratory rate observed during the PSV+VG epoch (Table 2) .
Variance in the inspiratory time, although not formally assessed and compared in the study, may have contributed to some of the differences seen between the two modes. In PSV+VG, the infant sets his or her own inspiratory time, whereas it was fixed at 0.35 seconds in the SIMV mode. We speculate that the immaturity of these infants' respiratory drives may contribute to this variability.
There was no difference in the dynamic lung compliance between the two modes. As also would be expected, the mean values for sCdyn, although not different between the modes of ventilation, are decreased from published values in normal premature and term infants. Dynamic compliance tends to be reduced compared to static compliance because of volume hysteresis.
The measurement of the EEV during each mode of ventilation was an important element of our study design. It is easily performed with immediate availability of results. In direct comparison between the two modes of ventilation, the EEV was significantly decreased in the PSV+VG mode. Because helium dilution was used, it is possible that gas trapping would have occurred with either mode of ventilation and not have been detected, as the technique we employed measures only gas volumes in continuity with ventilated spaces. The total respiratory rate, as noted, was increased during PSV+VG. We speculate that the increase in respiratory frequency in the PSV+VG group was secondary to a decreased EEV. A decrease in the EEV would elevate the alveolar and arterial pCO 2 , prompting an increase in respiratory frequency. The low EEV in the PSV+VG group is possibly related to the fixed V T in a ventilator-dependent subject. Without sighs and with borderline surfactant, the lungs will tend toward atelectasis. Considering the short time constant in infants with RDS and the adequate expiratory time, frequency dependency of compliance in either epoch was not likely the cause of an increased EEV in the SIMV group. If it contributed at all, it would have been to reduce the sCdyn during PSV+VG. Given that the mean EEV was <20 ml/kg during both modes of ventilation in the infants studied, a higher PEEP during both modes may have been therapeutically useful.
The design of our study did not allow for ventilator changes to be made based solely on the EEV measurement, but another clinical trial could be designed to do so. For example, a higher PEEP, and presumably a higher EEV, especially during the PSV+VG phase, might have produced more favorable short-term results for this mode. One study conducted before the era of intermittent ventilation and surfactant showed that infants on continuous positive airway pressure (CPAP), who had an EEV larger than average, required fewer days of CPAP and oxygen than those with a smaller volume. 15 Other studies have evaluated the EEV as a predictor of extubation failure or chronic oxygen dependency; 16, 17 but to our knowledge, there has been no trial of optimizing lung volume by measuring EEV and comparing the outcome of incidence of chronic lung injury. PSV and biologically variable ventilation both display inherent instability when assessed by mathematical modeling 18 and in animal models.
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The long-term effects of these more variable patterns of ventilation in neonatal lung diseases should be subjected to appropriate clinical trials before widespread use. Based upon the increased MAP and V E , decreased EEV, and no difference in the a/A ratio or sCdyn, we have no reason currently to recommend the routine use of PSV+VG for this specific population of infants with respiratory failure. It remains to be seen if PSV+VG, if used throughout a course of assisted ventilation, will result in a clinically meaningful outcome in smaller and/or sicker infants.
